Develops drug therapies to treat serious eye diseases, utilizing its proprietary SCS Microinjector technology.
Clearside Biomedical, Inc., a pioneering biopharmaceutical company headquartered in Alpharetta, Georgia, is dedicated to advancing the delivery of therapies to the back of the eye through the innovative suprachoroidal space. The company's flagship product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for the treatment of uveitis macular edema, offering a novel approach to addressing ocular inflammation.
In addition to XIPERE, Clearside Biomedical is actively developing CLS-AX, an axitinib injectable suspension currently in Phase 1/2a clinical trials. This therapeutic candidate aims to leverage the suprachoroidal injection route to potentially enhance treatment efficacy for ocular conditions. The company's pipeline also includes CLS-301, an integrin inhibitor suspension targeting diabetic macular edema and macular degeneration, underscoring its commitment to addressing diverse eye diseases through innovative therapeutic solutions.
Founded in 2011, Clearside Biomedical continues to expand its capabilities and collaborations within the biopharmaceutical industry. The company has established strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences, enhancing its ability to advance groundbreaking treatments and improve outcomes for patients worldwide with ocular disorders.